D-praziquantel / Sun Pharma - LARVOL DELTA

Activation of transient receptor potential channel Sm.(Schistosoma mansoni)TRPM by PZQ, enhanced Ca influx, spastic paralysis, and tegumental disrupture-the deadly cascade in parasitic schistosomes, other trematodes, and cestodes. (PubMed, Parasitol Res) - "After almost 50 years of praziquantel (PZQ) research, Park and Marchant (Trends Parasitol 36:182-194, 2020) described the Ca-permeable transient receptor potential (TRP) channel Sm.TRPM in Schistosoma mansoni as target of PZQ. These tegument damages are irreversible. As homologs of Sm.TRPM are also present in the other trematodes S. japonicum, S. haematobium, or Clonorchis sinensis and cestodes Taenia solium, Echinococcus multilocularis, or Hymenolepis microstoma (Park and Marchant, Trends Parasitol 36:182-194, 2020), it is suggested that a similar deadly cascade will be operating generally in PZQ-sensitive parasites."

Journal • Review • Psychiatry

Schistosomiasis vaccine development: update on human clinical trials. (PubMed, J Biomed Sci) - "The control of schistosomiasis over the last several decades has been centered on the mass drug administration (MDA) of praziquantel (PZQ), which is the only drug currently available for treatment. However, the general consensus in the field is that the integration of a viable vaccine with MDA and other control measures offer the best chance of achieving the goal of schistosomiasis elimination. This review focuses on the present status of schistosomiasis vaccine candidates in different phases of human clinical trials and provide some insight into future vaccine discovery and design."

Clinical • Journal • Review

Female genital schistosomiasis (FGS): from case reports to a call for concerted action against this neglected gynaecological disease. (PubMed) - "In recent years, control of neglected tropical diseases has been increasingly gaining momentum and interventions against schistosomiasis are being progressively scaled-up through expansion of donated praziquantel and preventive chemotherapy campaigns. Outside the long list of clinical descriptive reports beginning in 1899, there is presently a shocking gap in epidemiological assessment and a significant underestimation of the burden of FGS remains. The scarcity of integrated approaches to address female genital schistosomiasis calls for more concerted action in its detection, treatment and prevention alongside other concomitant women's health issues, otherwise female genital schistosomiasis will remain a neglected gynaecological disease."

Journal • Review • Biosimilar • Gene Therapies • Immunology